

November 9, 2017

The National Stock Exchange of India Limited
Exchange Plaza
Bandra Kurla Complex, Bandra (E)
Mumbai - 400051

The Bombay Stock Exchange Limited
15th Floor, Phiroze Jeejeeboy Towers
Dalal Street,
Mumbai – 400001

Subject: Unaudited Financial Results for the Quarter and Half Year ended September 30, 2017 and declaration of Interim Dividend

Ref: Regulation 30 & 33 of the SEBI (Listing Obligation and Disclosure Requirement) Regulations 2015 (hereinafter referred as Listing Regulations)

Dear Sir/Madam,

Please take note that the Board of Directors in their meeting held today i.e. November 9, 2017 approved the unaudited Financial Results (Standalone and Consolidated) of the Company for the Quarter and Half Year ended September 30, 2017.

A copy of the Results along with Limited Review Report issued by the Statutory Auditors M/s Deloitte Haskins & Sells, LLP on such financials for the Quarter and Half Year ended September 30, 2017 is attached herewith.

At the said Meeting, the Board of Directors have also declared an interim dividend of Rs. 1.50 per equity share (@ 15 % on a face value of Rs. 10/- per share) for the Financial Year 2017-18.

Also, kindly take note that the Board has fixed November 21, 2017 as the record date for the purpose of payment of interim dividend. The interim dividend will be paid by the Company on or after December 4, 2017.

The Board Meeting commenced at 11:45 AM and concluded at 2 PM.

We request you to please take the same on record.

Thanking You,

Yours Faithfully,

For Dr. Lal PathLabs Limited



Rajat Kalra
Company Secretary & Legal Head



Encl: As above

Independent Auditor's review report on review of Interim Financial Results

To the Board of Directors of
Dr. Lal PathLabs Limited (formerly Dr. Lal PathLabs Private Limited)

1. We have reviewed the accompanying Statement of Standalone Unaudited Ind AS Financial Results of **Dr. Lal PathLabs Limited (formerly Dr. Lal PathLabs Private Limited)** ("the Company"), for the quarter and six months ended 30 September, 2017 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated 5 July, 2016.


This Statement which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

As stated in Note ii of the Statement, we have not performed a review or audit of the figures relating to the corresponding quarter and six months ended 30 September, 2016 and of the figures relating to year ended 31 March, 2017, including the reconciliation of equity as on 31 March, 2017 and reconciliation of net profit for the quarter and half year ended 30 September, 2016 and for the year ended 31 March, 2017, between the previous GAAP and Indian Accounting Standards ("IND AS").

2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.
3. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated 5 July, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **Deloitte Haskins & Sells LLP**

Chartered Accountants
(Firm's Registration No. 117366W/W-100018)



Jitendra Agarwal

Jitendra Agarwal
Partner
(Membership No. 87104)

Place: New Delhi
Date: 9 November, 2017

Dr. Lal PathLabs Limited (formerly Dr. Lal PathLabs Private Limited)

CIN: L74899DL1995PLC065388

Regd. Office : Block E, Sector-18, Rohini, New Delhi- 110085, New Delhi

Corporate Office: 12th Floor, Tower B, SAS Tower, Medicity, Sector-38, Gurgaon - 122 001, Haryana

Phone: +91 124 3016500 | Fax: +91 124 4234468; Website: www.lalpathlabs.com; Email: cs@lalpathlabs.com

Statement of Standalone Unaudited Ind AS Financial Results for the quarter and six months ended 30 September, 2017

(Rs. in millions except as stated)

Particulars	3 months ended 30 September, 2017	Preceding 3 months ended 30 June, 2017	Corresponding 3 months ended 30 September, 2016	Year to date figures for current period ended 30 September, 2017	Year to date figures for previous period ended 30 September, 2016	Previous year ended 31 March, 2017
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)
			(See note II below)		(See note II below)	(See note II below)
1 (a) Revenue from operations	2,693	2,418	2,529	5,111	4,686	8,819
(b) Other income	77	81	82	158	145	283
Total Income	2,770	2,499	2,611	5,269	4,831	9,102
2 Expenses						
(a) Cost of materials consumed	576	506	580	1,082	1,051	1,912
(b) Employee benefits expense	434	423	382	857	723	1,474
(c) Depreciation and amortisation expense	71	65	62	136	122	264
(d) Finance costs	3	1	1	4	2	7
(e) Fees to collection centers/channel partners	335	295	278	630	521	1,001
(f) Other expenses	599	559	515	1,158	1,033	2,131
Total expenses	2,018	1,849	1,818	3,867	3,452	6,789
3 Profit before tax	752	650	793	1,402	1,379	2,313
4 Tax expense						
(a) Current tax	276	238	280	514	501	795
(b) Deferred tax	(26)	(19)	(15)	(45)	(37)	(7)
Total tax expense	250	219	265	469	464	788
5 Profit for the period (A)	502	431	528	933	915	1,525
6 Other comprehensive income						
-Items that will not be reclassified to profit or loss Remeasurement of the defined benefit plan (Net of tax)	1	1	(1)	2	(2)	(8)
Total other comprehensive income (B)	1	1	(1)	2	(2)	(8)
7 Total comprehensive income (A+B)	503	432	527	935	913	1,517
8 Paid-up equity share capital (Face Value of Rs. 10/- per share)	833	833	828	833	828	831
9 Earnings per share (Rs.) (not annualised)						
- Basic	6.15	5.30	6.48	11.44	11.25	18.67
- Diluted	6.14	5.29	6.44	11.43	11.17	18.60

Dr. Lal PathLabs Limited (formerly Dr. Lal PathLabs Private Limited)

Notes:

- i. The above results were reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on 9 November, 2017.
- ii. The financial results of the Company have been prepared in accordance with the Indian Accounting Standards (Ind AS) notified under Companies (Indian Accounting Standards) Rules 2015 (Ind AS) as amended by the Companies (Indian Accounting Standards) (Amendment) Rules, 2016. Beginning 1 April, 2017 the Company has for the first time adopted Ind AS with a transition date of 1 April 2016. These financial results (including for all the periods presented in accordance with Ind AS 101 - First time adoption of the Indian Accounting Standards) have been prepared in accordance with the recognition and measurement principles in Ind AS 34- Interim Financial Reporting, prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. The financial results include results for the quarter and six months ended 30 September, 2016 and year ended 31 March, 2017 which have not been subject to limited review/ audit.
- iii. Reconciliation of net profit between Indian GAAP as previously reported and the total comprehensive income as per Ind AS is as follows:

(Rs. in million)

Nature of Adjustments	Corresponding 3 months ended 30 September, 2016	Year to date figures for previous period ended 30 September, 2016	Previous year ended 31 March, 2017
Net Profit as per previous GAAP	514	889	1,472
Effect of recognising employee stock options cost at fair value	(1)	(2)	(6)
Effect of recognising actuarial (gain)/ loss on employee defined benefit liability under other comprehensive income (net of tax)	1	2	8
Effect of fair valuation of investments in mutual funds (net of tax)	3	4	9
Reversal of amortisation of goodwill previously booked in previous GAAP (net of tax)	10	19	37
Reversal of lease equalisation reserve created in previous GAAP (net of tax)	1	3	6
Others	-	-	(1)
Net Profit as per Ind AS (A)	528	915	1,525
Other Comprehensive Income (B)	(1)	(2)	(8)
Total Comprehensive Income as per Ind AS (A+B)	527	913	1,517

- iv. Reconciliation of total equity between Indian GAAP as previously reported and the total comprehensive income as per Ind AS is as follows:

Nature of Adjustments	(Rs. in million)
	As at 31 March, 2017
Total equity under previous GAAP (A)	5,825
Effect of measuring deposits (Loans & advances) at amortised cost value (net)	(5)
Effect of fair valuation of investments in mutual funds (net of tax)	9
Reversal of amortisation of goodwill previously booked in previous GAAP (net of tax)	(35)
Reversal of lease equalisation reserve created in previous GAAP (net of tax)	71
Total adjustment to equity (B)	40
Total equity under Ind AS (A+B)	5,865

- v. The Board of Directors in their meeting, held on 12 May, 2017, approved the "Scheme of Amalgamation" of Delta Ria and Pathology Private Limited with the Company w.e.f. 1 April, 2017 (the appointed date). As per the said scheme the undertaking of this company shall stand transferred to and vested in the Company on a going concern basis without any further act, deed of matter. The scheme of amalgamation is subject to approval by the National Company Law Tribunal and other statutory approvals.
- vi. The Board of Directors has approved an Interim Dividend of Rs. 1.50 per equity share (par value of Rs. 10/- each) at their meeting held today.
- vii. As approved in their Board Meeting dated 7 August, 2017, subsequent to the period end, the Company has acquired 70% investment in Dr. Lal Path Labs Bangladesh Private Limited, Bangladesh.
- viii. During the six months ended 30 September, 2017, the Company has issued 266,560 equity shares of face value of Rs. 10 each to the employees on exercise of employee stock options.
- ix. Based on the information reported to the Chief Operating Decision Maker (CODM) for the purpose of resource allocation and assessment of performance there are no reportable segments in accordance with the requirements of Indian Accounting Standard 108- 'Operating Segment Reporting', notified under the Companies (Indian Accounting Standard) Rules, 2015.
- x. Refer to Annexure - A for Statement of standalone Assets and Liabilities.

For and on behalf of the Board of Directors of Dr. Lal PathLabs Limited (formerly Dr. Lal PathLabs Private Limited)

(Hony) Brig. Dr. Arvind Lal
Chairman and Managing Director

Place: New Delhi
Date: 9 November, 2017

Arvind Lal

Dr. Lal PathLabs Limited (formerly Dr. Lal PathLabs Private Limited)		
Statement of standalone Assets and Liabilities		
(Rs. in millions except as stated)		
Particulars	As at 30 September, 2017	As at 31 March, 2017
	(Unaudited)	(Unaudited)
Assets		
1. Non-current assets		
(a) Property, plant and equipment	1,044	1,033
(b) Capital work-in-progress	423	153
(c) Goodwill	11	11
(d) Other intangible assets	145	166
(e) Intangible assets under development	19	19
(f) Financial assets		
(i) Investments	313	313
(ii) Loans	1	1
(iii) Other financial assets	185	145
(g) Non-current tax assets (net)	75	57
(h) Deferred tax assets (net)	176	132
(i) Other non-current assets	192	128
Total non-current assets	2,584	2,158
2. Current assets		
(a) Inventories	313	171
(b) Financial assets		
(i) Investments	995	1,029
(ii) Trade receivables	540	402
(iii) Cash and cash equivalents	154	135
(iv) Bank balances other than (iii) above	2,531	2,271
(v) Loans	3	2
(vi) Other financial assets	645	479
(c) Other current assets	193	115
Total current assets	5,374	4,604
Total assets	7,958	6,762
Equity and Liabilities		
1. Equity		
(a) Equity share capital	833	831
(b) Other equity	5,883	5,034
Total equity	6,716	5,865
2. Liabilities		
Non-current liabilities		
(a) Financial liabilities		
(i) Other financial liabilities	60	64
(b) Other non-current liabilities	5	8
Total non-current liabilities	65	72
Current liabilities		
(a) Financial liabilities		
(i) Trade payables	680	506
(ii) Other financial liabilities	194	154
(b) Provisions	81	66
(c) Current tax liabilities (net)	142	2
(d) Other current liabilities	80	97
Total current liabilities	1,177	825
Total liabilities	1,242	897
Total Equity and Liabilities	7,958	6,762

Independent Auditor's review report on review of Interim Financial Results

To the Board Of Directors of
Dr. Lal PathLabs Limited (formerly Dr. Lal PathLabs Private Limited)

1. We have reviewed the accompanying Statement of Consolidated Unaudited Ind AS Financial Results of **Dr. Lal PathLabs Limited (formerly Dr. Lal PathLabs Private Limited)** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), for the quarter and six months ended 30 September, 2017 ("the Statement") being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated 5 July, 2016.

This Statement, which is the responsibility of the Parent's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

As stated in Note iii of the Statement, we have not performed a review or audit of the figures relating to the corresponding quarter and six months ended 30 September, 2016 and of the figures relating to the year ended 31 March, 2017, including the reconciliation of equity as of 31 March, 2017 and reconciliation of net profit for the quarter and half year ended 30 September, 2016 and for year ended 31 March, 2017, between the previous GAAP and Indian Accounting Standards ("IND AS").

2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Parent's personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.
3. The Statement includes the results of the entities listed in Annexure A.
4. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated 5 July, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.



Deloitte Haskins & Sells LLP

5. The consolidated unaudited financial results includes the interim financial results of four subsidiaries which have not been reviewed by their auditors, whose interim financial results reflect total assets of Rs. 58 million as at 30 September, 2017, total revenue of Rs. 17 million and Rs. 35 million for the quarter and six months ended 30 September, 2017, respectively, and total loss after tax of Rs. 3 million and Rs. 2 million and total comprehensive loss of Rs. 3 million and Rs. 2 million for the quarter and six months ended 30 September, 2017 respectively, as considered in the consolidated unaudited Ind AS financial results. According to the information and explanations given to us by the Management, these interim financial results are not material to the Group.

Our report on the Statement is not modified in respect of our reliance on the interim financial results certified by the Management.

For **Deloitte Haskins & Sells LLP**
Chartered Accountants
(Firm's Registration No. 117366W/W-100018)



A handwritten signature in black ink, appearing to read "Jitendra Agarwal".

Jitendra Agarwal
Partner
(Membership No. 87104)

Place: New Delhi
Date: 9 November, 2017

Deloitte Haskins & Sells LLP

Annexure A

List of entities consolidated

S. No.	Name of the Entity
1	Paliwal Medicare Private Limited
2	Paliwal Diagnostics Private Limited
3	APL Institute of Clinical Laboratory & Research Private Limited
4	Delta Ria & Pathology Private Limited
5	Dr. Lal PathLabs Nepal Private Limited
6	Dr. Lal PathLabs International B.V.



Dr. Lal PathLabs Limited (formerly Dr. Lal PathLabs Private Limited)

CIN: L74899DL1995PLC065388

Regd. Office : Block E, Sector-18, Rohini, New Delhi- 110085, New Delhi

Corporate Office: 12th Floor, Tower B, SAS Tower, Medicity, Sector-38, Gurgaon - 122 001, Haryana

Phone: +91 124 3016500 | Fax: +91 124 4234468; Website: www.lalpathlabs.com; Email: cs@lalpathlabs.com

Statement of Consolidated Unaudited Ind AS Financial Results for the quarter and six months ended 30 September, 2017

(Rs. in millions except as stated)

Particulars	3 months ended 30 September, 2017	Preceding 3 months ended 30 June, 2017	Corresponding 3 months ended 30 September, 2016	Year to date figures for current period ended 30 September, 2017	Year to date figures for period ended 30 September, 2016	Previous year ended 31 March, 2017
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)
			(See note III below)		(See note III below)	(See note III below)
1 (a) Revenue from operations	2,781	2,493	2,622	5,274	4,850	9,124
(b) Other income	77	75	69	152	133	275
Total Income	2,858	2,568	2,691	5,426	4,983	9,399
2 Expenses						
(a) Cost of materials consumed	594	521	596	1,115	1,080	1,971
(b) Employee benefits expense	446	436	393	882	743	1,520
(c) Depreciation and amortisation expense	75	69	65	144	128	275
(d) Finance costs	3	1	1	4	2	7
(e) Fees to collection centers/channel partners	334	294	278	628	520	1,001
(f) Other expenses	628	587	555	1,215	1,102	2,258
Total expenses	2,080	1,908	1,888	3,988	3,575	7,032
3 Profits before tax	778	660	803	1,438	1,408	2,367
4 Tax expense						
(a) Current tax	285	244	289	530	517	820
(b) Deferred tax	(17)	(28)	(16)	(45)	(39)	(8)
Total tax expense	269	216	273	485	478	812
5 Profit for the period (A)	509	444	530	953	930	1,555
Attributable to:						
Shareholders of the Company	506	441	527	947	924	1,545
Non Controlling Interest	3	3	3	6	6	10
6 Other comprehensive income						
- Items that will not be reclassified to profit or loss	1	1	(1)	2	(2)	(7)
Remeasurement of the defined benefit plan (Net of tax)						
Total other comprehensive Income (B)	1	1	(1)	2	(2)	(7)
7 Total comprehensive income (A+B)	510	445	529	955	928	1,548
Attributable to:						
Shareholders of the Company	507	442	526	949	922	1,538
Non Controlling Interest	3	3	3	6	6	10
8 Paid-up equity share capital (Face Value of Rs. 10/- per share)	833	833	828	833	828	831
9 Earnings per share (Rs.) (not annualised)						
- Basic	6.19	5.42	6.47	11.61	11.35	18.92
- Diluted	6.19	5.41	6.43	11.60	11.27	18.85

Dr. Lal PathLabs Limited (formerly Dr. Lal PathLabs Private Limited)

Notes:

- i. The above consolidated results were reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on 9 November, 2017.
- ii. The above consolidated results represent consolidated results of the Company and its subsidiaries (together 'the Group').
- iii. The consolidated financial results of the Group have been prepared in accordance with the Indian Accounting Standards (Ind AS) notified under Companies (Indian Accounting Standards) Rules 2015 (Ind AS) as amended by the Companies (Indian Accounting Standards) (Amendment) Rules, 2016, Beginning 1 April, 2017 the Company has for the first time adopted Ind AS with a transition date of 1 April, 2016. These consolidated financial results (including for all the periods presented in accordance with Ind AS 101 - First time adoption of the Indian Accounting Standards) have been prepared in accordance with the recognition and measurement principles in Ind AS 34- Interim Financial Reporting, prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. The consolidated financial results include results for the quarter and six months ended 30 September, 2016 and year ended 31 March, 2017 which have not been subject to limited review/ audit.
- iv. Reconciliation of net profit between Indian GAAP as previously reported and the total comprehensive income as per Ind AS is as follows


Nature of Adjustments	(Rs. in millions)		
	Corresponding 3 months ended 30 September, 2016	Year to date figures for previous period ended 30 September, 2016	Previous year ended 31 March, 2017
Net Profit as per previous GAAP	528	930	1,552
Reversal of amortisation of goodwill previously booked in prior GAAP (net of tax)	(3)	(7)	(13)
Effect of fair valuation of investments in mutual funds (net of tax)	3	4	9
Effect of recognising actuarial (gain)/ loss on employee defined benefit liability under other comprehensive income (net of tax)	1	2	7
Reversal of lease equalisation reserve created in previous GAAP (net of tax)	2	3	7
Effect of recognising employee stock options cost at fair value	(1)	(2)	(6)
Others	-	-	(1)
Net Profit as per Ind AS (A)	530	930	1,555
Other Comprehensive Income (B)	(1)	(2)	(7)
Total Comprehensive Income as per Ind AS (A+B)	529	928	1,548

- v. Reconciliation of total equity between Indian GAAP as previously reported and the total comprehensive income as per Ind AS is as follows:

Nature of Adjustments	(Rs. in million)
	As at 31 March, 2017
Total equity under previous GAAP (A)	6,198
Impairment of Goodwill in accordance with Ind AS 101 (net of tax)	(296)
Effect of measuring deposits (Loans and advances) at amortised cost value (net of tax)	(5)
Effect of fair valuation of investments in mutual funds (net of tax)	10
Reversal of lease equalisation reserve booked in previous GAAP (net of tax)	73
Total adjustment to equity (B)	(218)
Total equity under Ind AS (A+B)	5,980

- vi. The Board of Directors in their meeting, held on 12 May, 2017, approved the "Scheme of Amalgamation" of Delta Ria and Pathology Private Limited with the Company i.e., 1 April, 2017 (the appointed date). As per the said scheme the undertaking of this company shall stand transferred to and vested in the Company on a going concern basis without any further act, deed of matter. The scheme of amalgamation is subject to approval by the National Company Law Tribunal and other statutory approvals.
- vii. The Board of Directors of the Parent Company has approved an Interim Dividend of Rs. 1.50 per equity share (par value of Rs. 10/- each) at their meeting held today.
- viii. As approved in their Board Meeting dated 7 August, 2017, subsequent to the period end, the Parent Company has acquired 70% investment in Dr. Lal Path Labs Bangladesh Private Limited, Bangladesh.
- ix. During the six months ended 30 September, 2017, the Company has issued 266,560 equity shares of face value of Rs. 10 each to the employees on exercise of employee stock options.
- x. Based on the information reported to the Chief Operating Decision Maker (CODM) for the purpose of resource allocation and assessment of performance there are no reportable segments in accordance with the requirements of Indian Accounting Standard 108- 'Operating Segment Reporting', notified under the Companies (Indian Accounting Standard) Rules, 2015.
- xi. Refer to Annexure - A for Statement of Consolidated Assets and Liabilities.

For and on behalf of the Board of Directors of Dr. Lal PathLabs Limited (formerly Dr. Lal PathLabs Private Limited)



(Hony) Brlg. Dr. Arvind Lal
Chairman and Managing Director

Place: New Delhi
Date: 9 November, 2017

Th

Dr. Lal PathLabs Limited (formerly Dr. Lal PathLabs Private Limited)		
Statement of Consolidated Assets and Liabilities		
(Rs. in millions except as stated)		
Particulars	As at 30 September, 2017 (Unaudited)	As at 31 March, 2017 (Unaudited)
Assets		
1 Non-current assets		
(a) Property, plant and equipment	1,111	1,079
(b) Capital work-in-progress	424	157
(c) Goodwill	279	279
(d) Other intangible assets	145	166
(e) Intangible assets under development	19	19
(f) Financial assets		
(i) Loans	1	1
(ii) Other financial assets	204	169
(g) Non-current tax assets (net)	81	70
(h) Deferred tax assets (net)	182	137
(i) Other non-current assets	192	130
Total non-current assets	2,638	2,207
2. Current assets		
(a) Inventories	322	179
(b) Financial assets		
(i) Investments	1,008	1,061
(ii) Trade receivables	549	418
(iii) Cash and cash equivalents	178	151
(iv) Bank balances other than (iii) above	2,576	2,287
(v) Loans	3	2
(vi) Other financial assets	652	481
(c) Other current assets	198	116
Total current assets	5,486	4,695
Total assets	8,124	6,902
Equity and Liabilities		
1. Equity		
(a) Equity share capital	833	831
(b) Other equity	5,987	5,124
Equity attributable to the owners of the Company	6,820	5,955
Non Controlling Interest	28	25
Total equity	6,848	5,980
2. Liabilities		
Non-current liabilities		
(a) Financial liabilities		
(i) Other financial liabilities	60	65
(b) Other non-current liabilities	5	8
Total non-current liabilities	65	73
Current liabilities		
(a) Financial liabilities		
(i) Trade payables	705	524
(ii) Other financial liabilities	197	155
(b) Provisions	84	69
(c) Current tax liabilities (net)	142	2
(d) Other current liabilities	83	99
Total current liabilities	1,211	849
Total liabilities	1,276	922
Total Equity and Liabilities	8,124	6,902